Vascular Perfusion Solutions — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vascular Perfusion Solutions is targeting a critical bottleneck in heart transplantation: the limited 4-6 hour preservation window with standard cold storage. The company's VP.S ENCORE® system is engineered to be a portable, cost-effective, and user-friendly device that uses a blood-free perfusate to potentially extend heart viability up to 8 hours, aiming to reduce organ discard rates and expand geographic matching. With FDA Breakthrough Device status secured in 2021 and preclinical data suggesting preservation up to 24 hours, the company is positioning its technology as a pragmatic solution to increase transplant volumes. Its long-term vision includes platform application for other organs and advanced therapies.

CardiovascularTransplantation

Technology Platform

Portable hypothermic oxygenated perfusion (HOP) system using blood-free perfusate and passive cooling, designed for organ preservation and transport.

Opportunities

The primary opportunity is to significantly increase the utilization of donor hearts by extending the preservation window, directly addressing a major cause of organ discard.

Success in heart transplantation creates a pathway to address the larger kidney transplant market and positions the company in emerging fields like xenotransplantation and organ banking.

Risk Factors

Key risks include failure to demonstrate safety and efficacy in upcoming clinical trials, regulatory hurdles in obtaining FDA pre-market approval, and intense competition from both approved and developmental organ perfusion systems.

Commercial adoption risk is also high, requiring a shift in entrenched clinical protocols.

Competitive Landscape

VPS competes in the organ perfusion market against established players like TransMedics (FDA-approved OCS™ system) and other developers of hypothermic and normothermic perfusion devices. Its key differentiators are a focus on portability, a blood-free perfusate, and designed cost-efficiency, positioning it as a potentially more accessible alternative to complex, high-cost systems.

More companies in Regenerative Medicine →More companies in United States →